Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Large Decrease in Short Interest

Indaptus Therapeutics, Inc. (NASDAQ:INDP) saw a significant decrease in short interest in June. As of June 30th, there was short interest totaling 137,594 shares, a decrease of 72.1% from the June 15th total of 493,245 shares. Based on an average daily trading volume, of 239,554 shares, the short-interest ratio is currently 0.6 days. Approximately 0.2% of the company’s shares are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 1.72% of Indaptus Therapeutics at the end of the most recent reporting period. 7.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

INDP has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Tuesday, April 21st. Wall Street Zen upgraded Indaptus Therapeutics to a “hold” rating in a research note on Saturday, June 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Indaptus Therapeutics currently has an average rating of “Sell”.

Indaptus Therapeutics Price Performance

NASDAQ:INDP traded up $0.13 during mid-day trading on Friday, hitting $2.63. 59,624 shares of the company’s stock were exchanged, compared to its average volume of 172,465. The company has a market cap of $297.82 million, a PE ratio of -0.17 and a beta of 1.11. Indaptus Therapeutics has a one year low of $0.92 and a one year high of $12.98. The business has a fifty day moving average price of $2.53 and a 200 day moving average price of $2.38.

Indaptus Therapeutics (NASDAQ:INDP) last announced its earnings results on Friday, May 15th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.87) by $1.64.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.